Focused On-demand Library for All-trans-retinol dehydrogenase [NAD(+)] ADH1B

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Alcohol dehydrogenase 1B; Alcohol dehydrogenase subunit beta

Alternative UPACC:

P00325; A8MYN5; B4DRS9; B4DVC3; Q13711; Q4ZGI9; Q96KI7


All-trans-retinol dehydrogenase [NAD(+)] ADH1B, also known as Alcohol dehydrogenase 1B and Alcohol dehydrogenase subunit beta, plays a pivotal role in retinoid metabolism. It catalyzes the NAD-dependent oxidation of all-trans-retinol and its derivatives, contributing significantly to the biological processes involving vitamin A. The enzyme exhibits a preference for the oxidative direction, showcasing higher efficiency in this pathway.

Therapeutic significance:

Understanding the role of All-trans-retinol dehydrogenase [NAD(+)] ADH1B could open doors to potential therapeutic strategies. Its involvement in retinoid metabolism suggests its potential impact on conditions related to vitamin A deficiency or excess, offering a promising avenue for research into novel treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.